FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

vvasnin	gton,	D.C.	20549

STATEMENT	OF CHAN	GES IN BE	NEFICIAL	OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burde	en
	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* BOGER JOSHUA S					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								(Check all applion X Director Officer		tor er (give title		10% Ov Other (s	ner
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE					06/	3. Date of Earliest Transaction (Month/Day/Year) 06/08/2016									below)			oelow)	
(Street) BOSTON MA 02210					- 4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(Si		(Zip)																
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/			tion	on 2A. Deemed Execution Date,		3.		4. Securities Acquired (A) or		(A) or		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			Instr. 4)
Common Stock 06/0				06/08/2	2016				M		5,130	A	\$35.3	5	5 273,355		D		
Common Stock 06/			06/08/2	016				S ⁽¹⁾		4,930	D	\$94.930	(2)(3)	268,425		D			
Common Stock 06/08/2				2016	16			S ⁽¹⁾		200	D	\$95.57	(2)(4)	268	3,225	D			
Common Stock												13		,286	I	4	401k		
Common Stock													122	2,700	I	1	Common Stock Held In Trust		
		Т	able II								posed of				wned				
1. Title of 2. Security Or Exercise (Month/Day/Year) 3A. Deemed Execution Date, if any		4. Transa	Transaction (Code (Instr. 1)		umber vative urities uired or posed D) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersi Form: Direct (Dor Indire (I) (Instr.	m: ect (D) ndirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$35.35	06/08/2016			M			5,130	(5))	07/19/2016	Common Stock	5,130	,	\$0.00	25,660)	D	

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- 2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$94.93 (range \$94.41 to \$95.40).
- 4. Open market sales reported on this line occurred at a weighted average price of \$95.57 (range \$95.56 to \$95.57).
- 5. Fully vested.

Remarks:

Michael LaCascia, Attorney-

06/10/2016

In-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.